Facebook Twitter Linkedin



Enrollees in Nigeria, Kenya and Tanzania


Total disbursed loan amount in USD


Number of patient visits to SafeCare facilities per month


Number of active clinics in the SafeCare program


Second-Line Antiretroviral Treatment Successfully Resuppresses Drug-Resistant HIV-1 After First-Line Failure: Prospective Cohort in Sub-Saharan Africa

Mar 23, 2012

Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line antiretroviral therapy in Africa. In adults who switched to boosted protease inhibitor-based regimens after first-line failure, HIV-RNA and genotypic resistance testing was performed at switch and after 12 months. Factors associated with treatment failure were assessed using logistic regression. Of 243 participants, 53% were predicted to receive partially active second-line regimens due to drug resistance. The risk of treatment failure was, however, not increased in these participants. In this African cohort, boosted protease inhibitors successfully resuppressed drug-resistant HIV after first-line failure.

Click here to read the full article.

Author: K. Sigaloff, R. Hamers, C. Wallis, C. Kityo, M. Siwale, P. Ive, M. Botes, K. Mandaliya, M. Wellington, A. Osibogun, W. Stevens, M. van Vugt, T. Rinke de Wit and the PharmAccess African Studies to Evaluate Resistance (PASER)

Date: March 2012


On 12 September 2016, OPIC, Calvert Foundation and two private investors announce expansion
PharmAccess and its German consultancy partner GFA have won a 27.3 million Euros tender from the German development bank KfW to improve access to healthcare for low-income pregnant women in 5 regions of Tanzania.
President Felipe Nyuse of Mozambique officially opened the University Clinic


A population-based study
Date: September, 2015

Research findings on Health Insurance Fund supported programs

Date: February, 2015